Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
| Autor: | Gert-Jan B. van Ommen, Niki Heuvelmans, G. Campion, Jan J.G.M. Verschuuren, J M Ad Sitsen, Jessica A. Sipkens, Brigitte E Burm, Gunnar Buyse, Nathalie Goemans, Judith C.T. van Deutekom, Sjef J. de Kimpe, Peter F. Ekhart, Gerard Johannes Platenburg, Anneke A.M. Janson, Niklas Darin, Annemieke Aartsma-Rus, Johanna T van den Akker, Mar Tulinius, Tjadine Holling |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Duchenne muscular dystrophy Injections Subcutaneous Oligonucleotides Eteplirsen Dystrophin Pharmacokinetics Internal medicine medicine Humans Muscle Strength Muscular dystrophy Child Muscle Skeletal Creatine Kinase Drisapersen biology Dose-Response Relationship Drug business.industry General Medicine Exons medicine.disease Muscular Dystrophy Duchenne Alternative Splicing Endocrinology Child Preschool Mutation biology.protein Systemic administration Exercise Test RNA Creatine kinase business |
| Popis: | Local intramuscular administration of the antisense oligonucleotide PRO051 in patients with Duchenne's muscular dystrophy with relevant mutations was previously reported to induce the skipping of exon 51 during pre-messenger RNA splicing of the dystrophin gene and to facilitate new dystrophin expression in muscle-fiber membranes. The present phase 1-2a study aimed to assess the safety, pharmacokinetics, and molecular and clinical effects of systemically administered PRO051.We administered weekly abdominal subcutaneous injections of PRO051 for 5 weeks in 12 patients, with each of four possible doses (0.5, 2.0, 4.0, and 6.0 mg per kilogram of body weight) given to 3 patients. Changes in RNA splicing and protein levels in the tibialis anterior muscle were assessed at two time points. All patients subsequently entered a 12-week open-label extension phase, during which they all received PRO051 at a dose of 6.0 mg per kilogram per week. Safety, pharmacokinetics, serum creatine kinase levels, and muscle strength and function were assessed.The most common adverse events were irritation at the administration site and, during the extension phase, mild and variable proteinuria and increased urinary α(1)-microglobulin levels; there were no serious adverse events. The mean terminal half-life of PRO051 in the circulation was 29 days. PRO051 induced detectable, specific exon-51 skipping at doses of 2.0 mg or more per kilogram. New dystrophin expression was observed between approximately 60% and 100% of muscle fibers in 10 of the 12 patients, as measured on post-treatment biopsy, which increased in a dose-dependent manner to up to 15.6% of the expression in healthy muscle. After the 12-week extension phase, there was a mean (±SD) improvement of 35.2±28.7 m (from the baseline of 384±121 m) on the 6-minute walk test.Systemically administered PRO051 showed dose-dependent molecular efficacy in patients with Duchenne's muscular dystrophy, with a modest improvement in the 6-minute walk test after 12 weeks of extended treatment. (Funded by Prosensa Therapeutics; Netherlands National Trial Register number, NTR1241.). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|